الفهرس 
introductionOnly 14 pages are availabe for public view
 |  | from | 109 |  |  |
| | | from | 109 | | |
Abstract
Abstract
Rotavirus (RV) causes a severe diarrheal illness, mostly in children under five-years of age. RV infection (RVI) is a common illness, affects both developed and developing countries in equal rates, approximately. However, more death resulted in poor/ low-income countries due to the absence of constricted and effective health care.
Nowadays, many attenuated RV vaccines have been approved for immunization against RVI. However, the attenuated vaccination drawbacks of elevated cost; low-efficacy in poor countries; strains reassortment risk; and intussusception events, stimulate a real need for developing of new RV vaccination approaches. That’s including the inactivated RV vaccination to avoid the active-virus related concerns.
The current study aimed to prepare a pentavalent, inactivated Rotavirus vaccine (IRVV) using the most prevalent strains, circulating in the Egyptian environment. The vaccine immunogenicity was evaluated, after that, in mice as a representing animal model. The selected immunity marker to be detected was the RV-specific IgG antibodies; owing to their high impact in RV immunization. The trial-inactivated pentavalent vaccine immunogenicity was compared with the Rotarix® attenuated vaccine. That’s to evaluate the immunogenicity of the inactivated approach against the attenuated commercially available one.
Abstract
MSc Thesis 2016 Page 2
As result of the variation in the antigenic content and dosing schedule between the trial-IRVV and Rotarix® vaccine, the comparative assessment was dependent on achieving IgG-antibodies level exceeding 1: 6400. That limit implies a less susceptibility of RVI.
The trial-IRVV was developed with Egyptian isolated strains of G1, G2, G3 and G9/ P[8], formulated with 5% sucrose and 2% polysorbate-80 and thermally inactivated at 60°C for 2 hrs. A part of the prepared vaccine was modified with Alum-adjuvant. IRVV and Alum-IRVV trials were injected, subcutaneously, into mice groups at 0, 21, 35 days intervals. In parallel, the reference mice group was vaccinated with Rotarix® vaccine twice on 0 and 28th days, as recommended by the Rotarix® manufacturer.
IgG antibodies elevation was achieved with the pentavalent IRVV/ IRVV-Alum formulas, as well as the Rotarix® reference vaccine. In all vaccine formulas, IgG antibodies were exceeding the limit of 1:6400, indicating a less susceptibility for RVI and a reasonable immunization.
Further intensive research is needed to reveal the heterotopic and intestinal immunization that could be achieved with the inactivated vaccination approach, besides, application of variant adjuvants to best modify the IRVV immunization pattern.